1Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania

2William B. Schwartz, MD, Division of Nephrology, Tufts Medical Center, Boston, Massachusetts

3Center for Drug Safety and Effectiveness, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

4Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland

5Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Correspondence: Dr. Thomas D. Nolin, Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, 206 Salk Pavilion 335 Sutherland Drive, Pittsburgh, PA 15216. Email: [email protected]

M.A.B. and A.C.R. contributed equally to this work.

Published online ahead of print. Publication date available at www.cjasn.org.

See related Patient Voice, “Time to Abandon Renalism: Patients with Kidney Diseases Deserve More,” and editorial, “Call for Greater Adoption of Recommended Standards during Cancer Drug Development to Improve Cancer Care with CKD,” on pages 419–420 and 430–432, respectively.